Biologics Contract Development Market Overview 2030
Biologics are genetically engineered proteins which are originated from genes of human. Biologic drugs target the specific parts of the human immune system. Biologics are completely different from chemically synthesized drugs. There is wide range of biologic products include blood components, somatic cells, recombinant gene therapies, vaccine, and allergenic. Biologics are constituted as nucleic acid, proteins, and tissue from living organisms. This products are isolated from sources such as animal, human, and microbes with the help of biotechnological methods. This product is very sensitive to contamination thus, biologics contract development exhibits high demand from pharmaceutical companies.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
There has been an increase in the demand for medical supplies to take care of infected population. Respiratory support devices such as atomizers, life-support machines, oxygen generators, and monitors are among the majorly used medical devices in primary clinical treatment. Moreover, COVID-19 has led to a huge surge in demand for medical supplies such as personal protective equipment including masks, gloves, and protective eyeglasses. There is an increase in the need for medical supplies, both from healthcare professionals and civil population for precautionary measures, owing to the rise in number of COVID-19 cases worldwide. Manufacturers of these products have a chance to capitalize this increased demand for medical supplies to ensure adequate and continuous supply of personal protective equipment in the market. Therefore, COVID-19 is expected to have a significant impact on the biologics contract development market.
Top Impacting Factors
- Increase in number of drug development procedures by pharmaceutical companies, surge in rate of drug approval by Food and Drug Administration, surge in usage of targeted drug therapies, rise in demand for personalized medication, and increase in cases of chronic diseases are the major factors that drive the growth of the biologics contract development market.
- In addition, increase in adoption of advanced technologies for biologic development, favourable environment for clinical trials in developing countries, surge in number of collaboration, contracts & mergers with local players to develop advance biologic products, and increase in demand for treatment of rare diseases are some factors that fuel the growth of the market.
- However, high cost associated with biologics production methods and lack of awareness regarding use of these products restrain the growth of the biologics contract development market.
- Contrarily, rise in development of greater manufacturing flexibility in biopharmaceutical sector are expected to offer lucrative opportunities for the expansion of the market.
Market Trends
New Product Launches to Flourish the Market
In 2021, Almac Group announced launch of biologics contract of testing and development solutions for expansion of their business. This expansion will help in development and testing of new biologics products.
In 2020, Lake Pharma In., announced launch of integrated chemistry and biologics services for streamlined antibody- drug conjugates development solutions for pharmaceutical and biotechnology sectors.
Key Benefits of the Report
- This study presents the analytical depiction of biologics contract development market industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the biologics contract development market share.
- The current market is quantitatively analyzed to highlight the biologics contract development market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.
Questions Answered in the Biologics Contract Development Market Report
- Which are the leading players active in the biologics contract development market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What is "biologics contract development"?
- What is "biologics contract development" market prediction in the future?
- Who are the leading global players in the "biologics contract development" market?
- What are the current trends and predicted trends?
- What are the key benefits of the "biologics contract development" market report?
Biologics Contract Development Market Report Highlights
| Aspects | Details |
 By Source |
|
 By Product Service |
|
 By Disease Indication |
|
 By Region |
|
 Key Market Players | SE Thermo Fisher (Patheon), Abzena Ltd., Fujifilm Diosynth Biotechnologies, Boehringer Ingelheim BioXcellence, STC Biologics, Inc., LakePharma, KBI Biopharma, WuXi Biologics, AGC Biologics, Bionova Scientific, Genscript Biotech Corporation |
Loading Table Of Content...
